Literature DB >> 6958483

The effect of budesonide on nasal allergen challenge in patients with seasonal rhinitis and on nasal peak flow in healthy volunteers.

E P Munch, B Weeke, S A Johansson.   

Abstract

The influence on nasal allergen challenge of three different doses of budesonide and placebo administered three hours before or twice daily for one week before challenge was investigated out of season in twelve patients suffering from allergic rhinitis due to grass or brich pollen. Budesonide and placebo administered three hours before challenge significantly reduced the fall in nasal peak flow, sneezes and secretion. After one week's treatment only budesonide caused further significant decrease in sneezes and secretion and a significant increase in nasal peak flow before and after challenge. No dose-response relation was found. In twelve healthy subjects one week's treatment with budesonide significantly increased nasal peak flow compared to placebo.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6958483

Source DB:  PubMed          Journal:  Eur J Respir Dis Suppl        ISSN: 0106-4347


  5 in total

1.  Peak flow nasal patency indices in patients operated for nasal obstruction.

Authors:  K Larsen; H Oxhøj; A Grøntved; S Kristensen
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

Review 2.  Pharmacologic treatment of rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Clin Rev Allergy       Date:  1984-08

Review 3.  Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

Review 4.  Topical nasal steroids for intermittent and persistent allergic rhinitis in children.

Authors:  J J Al Sayyad; Z Fedorowicz; D Alhashimi; A Jamal
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

5.  Hepatic drug-metabolizing enzymes and drug transporters in Wilson's disease patients with liver failure.

Authors:  Sylwia Szeląg-Pieniek; Stefan Oswald; Mariola Post; Joanna Łapczuk-Romańska; Marek Droździk; Mateusz Kurzawski
Journal:  Pharmacol Rep       Date:  2021-06-11       Impact factor: 3.024

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.